Form 4 for IMA ImageneBio, Inc.
Accepted 2026-07-28 16:05:06 ET · period of report 2026-07-25 · accession 0001803794-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-28 16:05 | 2026-07-25 | IMA | Yarema Kristin | CEO, Dir | M - OptEx | $0.00 | +38.4K | 123.8K | +45% | $0 |
| D | 2026-07-28 16:05 | 2026-07-25 | IMA | Yarema Kristin | CEO, Dir | J - Other | $0.00 | +115.1K | 238.9K | +93% | $0 |
| D | 2026-07-28 16:05 | 2026-07-25 | IMA | Yarema Kristin | CEO, Dir | M - OptEx | $0.00 | -38.4K | 115.1K | -25% | $0 |
| D | 2026-07-28 16:05 | 2026-07-25 | IMA | Yarema Kristin | CEO, Dir | J - Other | $0.00 | -115.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-25 | M | A | 38,376 | $0.00 | 123,776 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-25 | J | A | 115,129 | $0.00 | 238,905 | D | — | — | (F1) On July 28, 2025, the Reporting Person was granted restricted stock units ("RSUs"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock. (F1) On July 28, 2025, the Reporting Person was granted restricted stock units ("RSUs"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock. (F1) On July 28, 2025, the Reporting Person was granted restricted stock units ("RSUs"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock. |
| 3 | Derivative | Restricted Stock Units | 2026-07-25 | M | D | 38,376 | $0.00 | 115,129 | D | — · — to — | 38,376 Common Stock | (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F3) The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates. (F3) The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates. |
| 4 | Derivative | Restricted Stock Units | 2026-07-25 | J | D | 115,129 | $0.00 | 0 | D | — · — to — | 115,129 Common Stock | (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F1) On July 28, 2025, the Reporting Person was granted restricted stock units ("RSUs"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock. (F3) The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates. (F3) The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates. |